MedPath

Surgical Conditions During Vocal Cord Surgery Requiring Jet Ventilation With Moderate vs. Deep Neuromuscular Block

Phase 1
Terminated
Conditions
High-Frequency Jet Ventilation
Vocal Cord Resection
Interventions
Registration Number
NCT02888067
Lead Sponsor
Thomas Schricker
Brief Summary

The purpose of this study is to determine whether deep neuromuscular blockade provides better surgical conditions than moderate neuromuscular blockade in patients undergoing vocal cord resections requiring jet ventilation.

Detailed Description

To optimize anatomical exposure and to minimize direct manipulation of local lesions endotracheal intubation often is avoided in patients undergoing vocal cord surgery.

Instead intermittent so called jet ventilation is carried out by using the Hunsaker Mon-jet tube. The safe conduct of these procedures requires full muscle paralysis. In clinical practice, however, deep neuromuscular blockade (NMB) usually cannot be established for this relatively short surgery (\<1h) because of an increased risk of prolonged NMB and postoperative ventilation.

The novel neuromuscular blockade reversal agent sugammadex may prove particularly useful in this patient population because it allows fast and reliable reversal of even deep NMB. Deeper muscle paralysis during vocal cord surgery may be associated with better surgical conditions.

The purpose of this study is to determine whether deep neuromuscular blockade provides better surgical conditions than moderate neuromuscular blockade in patients undergoing vocal cord resections requiring jet ventilation.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
12
Inclusion Criteria
  • Elective vocal cord resection with an expected length of the procedure longer than 20 minutes and requiring jet ventilation
Exclusion Criteria
  • Patients younger than 18 years old
  • Patients unable to give written informed consent
  • Patients with known or suspected neuromuscular disease
  • Patients with allergies to medications to be used during anesthesia
  • Patients with a (family) history of malignant hyperthermia
  • Patients with renal insufficiency (serum creatinine >2 times normal or a glomerular filtration rate <60 ml/h)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Moderate neuromuscular blockade (MNB)Rocuronium bromide 0.5 mg/kgThe goal is to realize a moderate NMB (TOF 1-2 twitches). NMB will be induced with a bolus dose of rocuronium (Non-depolarizing Skeletal Neuromuscular Blocking Agent). If the target TOF values was not reached bolus doses of rocuronium (5 mg) will be given to achieve the target. This represents the standard care in our institution for this type of surgery. At the end of surgery, neuromuscular blockade in all patients will be reversed by sugammadex: patients in the moderate neuromuscular blockade group will receive sugammadex (Selective Relaxant Binding Agent).
Deep neuromuscular blockade (MNB)Rocuronium bromide 1.0 mg/kgThe goal is to realize a deep MNB (TOF zero twitches). NMB will be induced with a bolus dose of rocuronium (Non-depolarizing Skeletal Neuromuscular Blocking Agent). If the target TOF values was not reached bolus doses of rocuronium (5 mg) will be given to achieve the target. At the end of surgery, neuromuscular blockade in all patients will be reversed by sugammadex: patients in the deep neuromuscular blockade group will receive sugammadex (Selective Relaxant Binding Agent).
Moderate neuromuscular blockade (MNB)Sugammadex sodium 2 mg/kgThe goal is to realize a moderate NMB (TOF 1-2 twitches). NMB will be induced with a bolus dose of rocuronium (Non-depolarizing Skeletal Neuromuscular Blocking Agent). If the target TOF values was not reached bolus doses of rocuronium (5 mg) will be given to achieve the target. This represents the standard care in our institution for this type of surgery. At the end of surgery, neuromuscular blockade in all patients will be reversed by sugammadex: patients in the moderate neuromuscular blockade group will receive sugammadex (Selective Relaxant Binding Agent).
Deep neuromuscular blockade (MNB)Sugammadex sodium 4 mg/kgThe goal is to realize a deep MNB (TOF zero twitches). NMB will be induced with a bolus dose of rocuronium (Non-depolarizing Skeletal Neuromuscular Blocking Agent). If the target TOF values was not reached bolus doses of rocuronium (5 mg) will be given to achieve the target. At the end of surgery, neuromuscular blockade in all patients will be reversed by sugammadex: patients in the deep neuromuscular blockade group will receive sugammadex (Selective Relaxant Binding Agent).
Primary Outcome Measures
NameTimeMethod
Five-point surgical rating scale (SRS)during surgery, an average period of 50 minutes

Surgical conditions during surgery will be assessed by the surgeon using a five-point surgical rating scale at 10 minutes intervals

Secondary Outcome Measures
NameTimeMethod
Drug dosagesThrough study completion, an average of 4 hours

Drugs and dosages used during the study

Time to extubationDuring the stay in the operation room, an average of 60 minutes

Time from reversal to optimal extubation conditions (TOF ratio \<0.9)

Heart rateDuring the stay in the operation and recovery room, an average of 4 hours
Arterial blood pressureDuring the stay in the operation and recovery room, an average of 4 hours
Oxygen saturationDuring the stay in the operation and recovery room, an average of 4 hours
Respiratory rateDuring the stay in the operation and recovery room, an average of 4 hours
Body temperatureDuring the stay in the operation and recovery room, an average of 4 hours
Duration of surgeryDuring the stay in the operation room, an average of 50 minutes
Duration of post-anesthesia care unit (PACU) stayDuring the stay in the recovery room, an average of 3 hours

Time spent in the PACU

Pain scoreDuring the stay in the operation and recovery room, an average of 4 hours

On an 11-point numerical rating scale from 0 = no pain, to 10 = most severe pain imaginable at PACU

Occurence of nausea/vomitingDuring the stay in the operation and recovery room, an average of 4 hours
SedationDuring the stay in the operation and recovery room, an average of 4 hours

On a five-point scale ranging from 0 = normal alertness to 5 = not aroused by a painful stimulus at PACU

Trial Locations

Locations (1)

MUHC

🇨🇦

Montreal, Quebec, Canada

© Copyright 2025. All Rights Reserved by MedPath